治疗前中性粒细胞和淋巴细胞计数对手术切除的头颈部鳞状细胞癌的预后判断
本研究对一项随机临床试验中681例手术切除后切缘阳性或淋巴结外侵犯的头颈部鳞状细胞癌患者进行二次分析,评估治疗前中性粒细胞计数、淋巴细胞计数及中性粒细胞-淋巴细胞比值与总生存和无病生存的关系。结果显示治疗前中性粒细胞计数升高与总生存降低显著相关(HR 1.56),淋巴细胞计数升高亦与总生存降低相关(HR 1.34),而中性粒细胞-淋巴细胞比值升高对总生存无显著影响(HR 1.09)。
要点
- 治疗前中性粒细胞计数升高与总生存降低显著相关(HR 1.56)。
- 治疗前淋巴细胞计数升高与总生存降低相关(HR 1.34)。
- 中性粒细胞-淋巴细胞比值升高对总生存无显著影响(HR 1.09)。
核心结论
- 治疗前中性粒细胞计数升高在所有患者和亚组中均与生存降低密切相关。
- 淋巴细胞计数仅在总体患者分析中与总生存显著相关。
- 中性粒细胞-淋巴细胞比值与总生存降低的关联无统计学显著性。
- 这些生物标志物在口咽癌患者中可能提供更大的预后价值,且似乎与总生存的关联强于无病生存。
研究设计与样本
- 对一项随机临床试验(ClinicalTrials.gov标识NCT00424255)进行二次分析,纳入681例手术切除且切缘阳性或淋巴结外侵犯的头颈部鳞状细胞癌患者,患者接受辅助放化疗联合或不联合拉帕替尼。
主要发现
- 治疗前中性粒细胞计数高与总生存降低显著相关(HR 1.56;95% CI:1.19-2.05)。
- 治疗前淋巴细胞计数高与总生存降低显著相关(HR 1.34;95% CI:1.01-1.79)。
- 治疗前中性粒细胞-淋巴细胞比值高对总生存无显著影响(HR 1.09;95% CI:0.81-1.47)。
- 亚组分析显示,高中性粒细胞计数在口咽癌、非口咽癌和HPV阴性亚组中均与总生存显著降低相关。
- 高中性粒细胞计数、淋巴细胞计数和中性粒细胞-淋巴细胞比值对无病生存均无显著影响。
关键数值与推荐
- 原文未报告
临床怎么用
- 原文未据此给出推荐
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hematological markers, such as neutrophils (ANC), lymphocyte (ALC), and neutrophil-lymphocyte ratio (NLR), may serve as indicators of systemic inflammation and immune response in head and neck squamous cell carcinoma (HNSCC). However, their prognostic significance across HNSCC subtypes remains to be fully elucidated. METHODS: We conducted a secondary analysis of a randomized clinical trial involving patients with surgically resected HNSCC with either positive margins or extranodal extension. These patients received either adjuvant chemoradiation with or without lapatinib. We explored the correlation between pre-therapy ANC, ALC, and NLR levels and overall survival (OS) as well as disease-free survival (DFS). A sub-group analysis examined potential links between these markers, primary tumor location, and HPV status. RESULTS: Of the 688 patients in the trial, we included 681 patients with documented pre-therapy ANC and ALC values. High pre-therapy ANC and ALC were significantly associated with reduced OS (HR, 1.56; 95% CI: 1.19-2.05) and (HR, 1.34; 95% CI: 1.01-1.79), respectively. High NLR did not significantly affect OS (HR, 1.09; 95% CI: 0.81-1.47). Subgroup analysis indicated significantly reduced OS in patients with high ANC across oropharyngeal, non-oropharyngeal, and HPV-negative subtypes. High ANC, ALC, and NLR did not impact DFS notably. CONCLUSION: Elevated pre-therapy ANC is strongly associated with decreased survival across all patients and subgroups, ALC was only significant in the general patient analysis. NLR's association with reduced OS was not statistically significant. These biomarkers may provide greater prognostic value in patients with oropharyngeal cancer and seemed to be more strongly associated with OS than DFS. TRIAL REGISTRATION: Clinicaltrials.gov identifier: NCT00424255; URL: https://clinicaltrials.gov/ct2/show/study/NCT00424255.
引用
- Sunkara PR, Chow E, Waitzman J, et al. The Prognostication of Surgically Resected Head and Neck Squamous Cell Carcinoma Using Pre-Therapy Neutrophil and Lymphocyte Counts. Head Neck. 2024. PMID: 39415507. doi:10.1002/hed.27949
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。